Labiotech.eu

News and Trends 25 Feb 2015

Cellectis is preparing its IPO in the U.S

Cellectis is a company focused on developing immunotherapies based on gene edited engineered CAR-T cells. The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. With 15 years of expertise, Cellectis is already listed on the NYSE Alternext market (ticker: ALCLS) and now preparing its IPO to be listed on the […]

February 25, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 24 Feb 2015

Cobra Biologics and Manchester University Awarded €296.4K

The University of Manchester and Cobra Biologics, biologics and pharmaceuticals manufacturer, have been awarded €296.4K by Innovate UK and the Biotechnology and Biological Sciences Research Council (BBSRC). The project is one of the only 23 which will share almost €27.3M given away by the competition that intends to bring innovative biotechnology projects to market. The joint […]

February 24, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Feb 2015

Adimab, the secret weapon of the Big Pharma companies

After establishing discovery collaborations with over 30 companies during the past five years (Roche, Pfizer, Genentech, Novartis, Merck, Lilly, Celgene, Novo Nordisk and GSK), it is today with Sanofi that the biotech company Adimab enters into partnership for the development of bispecific antibodies. Adimab integrated antibody discovery and optimization platform, offers unprecedent speed to purify […]

February 23, 2015 - 2 minutesmins - By Cédric Brock

News and Trends 22 Feb 2015

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell Leukemia/Lymphoma (ATL/L). ATL/L is a rare malignancy of a certain type of white cells, T-Lymphocytes, caused by the Human T-Cell Lymphotropic Virus type […]

February 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Feb 2015

Succesfull Phase II for Novo Nordisk’s new diabetes treatment

Good news for diabetes mellitus type 2 patients, as Novo Nordisk announced positive results for phase II trial with oral semaglutide. Novo Nordisk successfully completed the phase II trial for OG217SC, an oral formulation of the longacting GLP-1 analogue semaglutide. Confirming the primary end-point of the trial, all doses of oral semaglutide were statistically significantly […]

February 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 Feb 2015

GNA Biosolutions Leads the Consortium for Ultra-Fast Detection of Ebola

The ultra-fast diagnostic instruments developer, GNA Biosolutions (GNA), started the FILODIAG (Filovirus Diagnostics) project for developing a high-speed Ebola detection system based on GNA’s novel Laser PCR technology. There is an urgent need for fast and accurate diagnostic tests in the current and any future Ebola crisis. The rapid diagnosis of Ebola during early and […]

February 20, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 20 Feb 2015

2014, an amazing year for CARMAT

CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people with irreversible terminal heart failure. This concerns the sickest of the 20 million patients affected by this progressive disease in Europe and the United States. 2014 was an eventful year for the company, the publication of 2014 annual […]

February 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 19 Feb 2015

Lead Pharma partners with Sanofi to beat Autoimmune Diseases

Lead Pharma is a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer. It has entered into a research collaboration with big-shot Sanofi to develop small molecule therapies directed against the nuclear hormone receptor ROR gamma t (RORyt) to treat a broad range of autoimmune disorders. A big news for this Netherland-based Biotech […]

February 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Feb 2015

#BioFigures: 3,000 whole genomes sequenced to fight Parkinson!

WHO? 23andMe, founded in 2006, is the leading personal genetics company dedicated to helping people access, understand and benefit from the human genome. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. Photo credit: 23andMe WHAT? 23andMe, announced an agreement with Genentech, a member of the Swiss Roche Group, […]

February 18, 2015 - 2 minutesmins - By Marie Godar

News and Trends 18 Feb 2015

Highway to Brain

Researchers in Barcelona have developed a shuttle to transport drugs into the brain, running through the blood-brain barrier. If there is an irreplaceable organ, for the moment, that’s the brain. The gray matter is not only protected by the skull, but also by a barrier of cells that tightly regulates the transport of substances into this […]

February 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Feb 2015

Great news for Great Britain’s synthetic biology

British government will inject the impressive amount of £40M to reinforce UK’s leading position in synthetic biology. UK Business Secretary Vince Cable has announced a £40M investment in UK synthetic biology at the Manchester Institute for Biotechnology. The majority of this investment, £32M, will be used to establish three new Synthetic Biology Research Centres at […]

February 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Feb 2015

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company. GlycoVaxyn’s innovative biological conjugation platform originates enables the development of […]

February 14, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cellectis is preparing its IPO in the U.S

Cobra Biologics and Manchester University Awarded €296.4K

Adimab, the secret weapon of the Big Pharma companies

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

Succesfull Phase II for Novo Nordisk’s new diabetes treatment

GNA Biosolutions Leads the Consortium for Ultra-Fast Detection of Ebola

2014, an amazing year for CARMAT

Lead Pharma partners with Sanofi to beat Autoimmune Diseases

#BioFigures: 3,000 whole genomes sequenced to fight Parkinson!

Highway to Brain

Great news for Great Britain’s synthetic biology

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!